| Study | Outcome (unit) | Followup (years) | N Analyzed | Group | Results | Between Group Difference |
| --- | --- | --- | --- | --- | --- | --- |
| AMIS, 198075Fair | Total mortality (number of participants) | 3 | 2267 | ASA | 218 (9.6%) | NR |
| 2257 | Placebo | 199 (8.8%) |
| 3.2 | 2267 | ASA | 245 (10.8%) | ASA vs. Placebo: Z-score 1.27, p=NR |
| 2257 | Placebo | 219 (9.7%) |
| 2267 | ASA | 238 (10.5%)\* | ASA vs. Placebo: Cox Z-score 0.02, p=NR\* |
| 2257 | Placebo | 226 (10.0%)\* |
| Baron, 2003 (AFPPS)77Good (KQ1); Fair (KQ2,KQ6) | Death (number of participants) | 2.7 | 372 | ASA 325 | 4 (1.1%) | All Groups: p=0.93 |
| 377 | ASA 81 | 3 (0.8%) |
| 372 | Placebo | 3 (0.8%) |
| Becattini, 2012 (WARFASA)78Fair | Death (number of participants) | 2 | 205 | ASA | 6 (2.9%) | ASA vs. Placebo: HR 1.04 (95% CI, 0.32 to 3.42), p=0.95 |
| 197 | Placebo | 5 (2.5%) |
| Death (percent per year) | 2 | 205 | ASA | 1.4 (NR) | NR |
| 197 | Placebo | 1.3 (NR) |
| Belch, 2008 (POPADAD)57Fair | Death (any cause) (number of participants) | 6.7 | 318 | ASA alone | 38 (12%) | ASA vs. No ASA: HR 0.93 (95% CI, 0.71 to 1.24), p=0.63 |
| 320 | ASA + antioxidant | 56 (18%) |
| 320 | Antioxidant alone | 59 (18%) |
| 318 | Placebo alone | 42 (13%) |
| Brighton, 2012 (ASPIRE)58Good | Death (number of participants) | 3.1 | 411 | ASA | 16 (3.9%) | NR |
| 411 | Placebo | 18 (4.4%) |
| CDPRG, 1980 (CDPA)59Good | All-cause mortality (not cumulative) (number of participants) | 1 | 745 | ASA | 25 (NR) | NR |
| 755 | Placebo | 31 (NR) |
| 2 | 564 | ASA | 14 (NR) |
| 562 | Placebo | 31 (NR |
| 2.33 | 140 | ASA | 5 (NR) |
| 138 | Placebo | 2 (NR) |
| All-cause mortality, cumulative (per 100 person-years) | 1 | 745 | ASA | 3.30 (0.68) | ASA vs. Placebo: Z-value -0.75 (95% CI, -2.61 to 1.17), p=NR |
| 755 | Placebo | 4.02 (0.68) |
| 2 | 564 | ASA | 5.63 (1.02) | ASA vs. Placebo: Z-value -2.51 (95% CI, -6.45 to -0.79), p=NR |
| 562 | Placebo | 9.25 (1.02) |
| 2.33 | 140 | ASA | 6.74 (1.09) | ASA vs. Placebo: Z-value -1.91 (95% CI, -5.96 to 0.08), p=NR |
| 138 | Placebo | 9.68 (1.09) |
| Deaths (number of participants) | 1.8 | 758 | ASA | 43 (5.7%)† | NR |
| 1.8 | 771 | Placebo | 65 (8.4%)† |
| 1.8 | 758 | ASA | 44 (5.8%) | NR |
| 1.8 | 771 | Placebo | 64 (8.3%) |
| Cook, 2005 (WHS)60Good (KQ1,KQ2); Fair (KQ6) | Any death (number of participants)) | 10.1 | 19934 | ASA | 609 (3.1%) | ASA vs. No ASA: RR 0.95 (95% CI, 0.85 to 1.06), p=0.32‡ |
| 19942 | No ASA | 642 (3.2%) |
| *Cook, 2013 (Companion publication to Cook, 2005)88**Good* | *Any death (number of participants)* | *18* | *19934* | *ASA* | *1744 (8.7%)* | *ASA vs. No ASA: HR 1.00 (95% CI, 0.94 to 1.07), p≥0.99‡* |
| *19942* | *No ASA* | *1728 (8.7%)* |
| Cote, 1995 (ACBS)79Fair | Death (combined vascular and nonvascular) (number of participants) | 2.4 | 188 | ASA | 11 (5.9%) | NR |
| 184 | Placebo | 13 (7.1%) |
| de Gaetano, 2001 (PPP)61Fair | Total death (number of participants) | 3.6 | 2226 | ASA | 62 (2.8%) | ASA vs. No ASA: RR 0.81 (95% CI, 0.58 to 1.13), p=NR |
| 2269 | No ASA | 78 (3.4%) |
| Diener, 1997 (ESPS-2)62Good | Death (number of participants) | 2 | 1649 | ASA | 182 (11.0%) | ASA vs. Placebo: Risk Reduction 10.9 (8.6), p=0.204; OR 0.88 (95% CI, 0.71 to 1.09), p=NR |
| 1649 | Placebo | 202 (12.2%) |
| EAFT, 199363Fair | All deaths (% per year) | 838 p-y | 404 | ASA | 11 (NR) | NR |
| 715 p-y | 378 | Placebo | 12 (NR) |
| All deaths (number of participants) | 2.3 | 404 | ASA | 102 (25.2%) | ASA vs. Placebo: HR 0.91 (95% CI, 0.69 to 1.20), p=0.48 |
| 378 | Placebo | 99 (26.2%) |
| ETDRS, 199264Good | Death-all causes (5-year life table rate) | 5 | 1855 | ASA | 14.9 (NR) | ASA vs. Placebo: RR 0.91 (99% CI, 0.75 to 1.11), p=0.24§ |
| 1856 | Placebo | 12.1 (NR) |
| Death-all causes (number of participants) | 5 | 1856 | ASA | 340 (18.3%) | ASA vs. Placebo: Z-value -1.10, p=NR |
| 1855 | Placebo | 366 (19.7%) |
| Farrell, 1991 (UK-TIA)65Fair | All-cause mortality (number of participants) | 4 | 815 | ASA 1200 | 112 (13.7%) | NR |
| 806 | ASA 300 | 109 (13.5%) |
| 814 | Placebo | 122 (15.0%) |
| Fowkes, 2010 (AAA)66Good | All-cause mortality (number of participants) | 8.2 | 1675 | ASA | 176 (10.5%) | NR |
| 1675 | Placebo | 186 (11.1%) |
| All-cause mortality, incidence rate (per 1,000 person-years) | 8.2 | 1675 | ASA | 12.8 (NR) | ASA vs. Placebo: HR 0.95 (95% CI, 0.77 to 1.16), p=NR |
| 1675 | Placebo | 13.5 (NR) |
| Hansson, 1998 (HOT)67Fair | Deaths (number of participants) | 3.8 | 9399 | ASA | 284 (3.0%) | ASA vs. Placebo: RR 0.93 (95% CI, 0.79 to 1.09), p=0.36 |
| 9391 | Placebo | 305 (3.2%) |
| Deaths (per 1,000 patient-years) | 3.8 | 9399 | ASA | 8.0 (NR) | NR |
| 9391 | Placebo | 8.6 (NR) |
| Juul-Moller, 1992 (SAPAT)54Fair | Deaths (number of participants) | 4.2 | 1009 | ASA | 82 (8.1%) | ASA vs. Placebo: % Change -22, p=0.103 |
| 1026 | No ASA | 106 (10.3%) |
| Logan, 2008 (ukCAP)68Fair | Deaths, occurring while on study medication or w/in 6 months of completing treatment (number of participants) | 3.4 | 472 | ASA | 3 (0.6%) | NR |
| 467 | No ASA | 5 (1.1%) |
| Died (number of participants) | 3.4 | 236 | ASA alone | 8 (3.4%) | NR |
| 236 | ASA + folic acid | 4 (1.7%) |
| 234 | Folic acid alone | 4 (1.7%) |
| 233 | Placebo alone | 7 (3.0%) |
| MRC, 1998 (TPT)69Good | Death, all causes (number of participants) | 6.8 | 1268 | ASA | 113 (8.9%) | NR |
| 1272 | Placebo | 110 (8.6%) |
| Death, all causes (per 1,000 person-years) | 6.8 | 1268 | ASA | 13.6 (NR) | NR |
| 1272 | Placebo | 13.1 (NR) |
| Nelson, 2008 (ASPREE)53Fair | Death (number of participants) | 1 | NR | ASA | 0 (0%) | NR |
| NR | Placebo | 0 (0%) |
| Ogawa, 2008 (JPAD)70Fair | All-cause mortality (number of participants) | 4.37 | 1262 | ASA | 34 (2.7%) | ASA vs. No ASA: HR 0.90 (95% CI, 0.57 to 1.14), p=0.67 |
| 1277 | No ASA | 38 (3.0%) |
| PARIS, 198071Good | All-cause mortality (number of participants) | 3.4 | 810 | ASA | 85 (10.5%) | ASA vs. Placebo: Z-value -1.06, p=NR║ |
| 406 | Placebo | 52 (12.8%) |
| Total death (event rate) | 1 | 810 | ASA | 3.2 (NR) | ASA vs. Placebo: % Reduction 5.9, p=Z-value: -0.23 |
| 406 | Placebo | 3.4 (NR) |
| 1.33 | 810 | ASA | 4.3 (NR) | ASA vs. Placebo: % Reduction 8.5, p=Z-value: -0.30 |
| 406 | Placebo | 4.7 (NR) |
| 1.67 | 810 | ASA | 5.4 (NR) | ASA vs. Placebo: % Reduction 23.9, p=Z-value: -1.25 |
| 406 | Placebo | 7.1 (NR) |
| 2 | 810 | ASA | 5.6 (NR) | ASA vs. Placebo: % Reduction 29.1, p=Z-value: -1.60 |
| 406 | Placebo | 7.9 (NR) |
| 3 | 810 | ASA | 9.0 (NR) | ASA vs. Placebo: % Reduction 21.1, p=Z-value: -1.31 |
| 406 | Placebo | 11.4 (NR) |
| Petersen, 1989 (Copenhagen AFASAK)80Fair | Death (number of participants) | 2 | 336 | ASA | NR (NR) | ASA vs. Placebo (citric acid): p=NSD |
| 336 | Placebo (citric acid) | NR (NR) |
| Peto, 1988 (BMD)72Fair | All-cause mortality (per 10,000 person-years) | 6 | 3429 | ASA | 143.5 (NR) | NR |
| 1710 | No ASA | 159.5 (NR) |
| PHS, 198973Good (KQ1); Fair (KQ6) | All-cause mortality (number of participants) | 5 | 11037 | ASA | 217 (2.0%) | ASA vs. Placebo: RR 0.96 (95% CI, 0.80 to 1.14), p=0.64¶ |
| 11034 | Placebo | 227 (2.1%) |
| All-cause mortality, confirmed cause (number of participants) | 5 | 11037 | ASA | 205 (1.9%) | ASA vs. Placebo: RR 0.95 (95% CI, 0.79 to 1.15), p=0.60¶ |
| 11034 | Placebo | 216 (2.0%) |
| SALT, 199174Good | Total death (fatal stroke and non-stroke deaths) (number of participants) | 2.67 | 676 | ASA | 61 (9.0%) | NR |
| 684 | Placebo | 69 (10.1%) |
| Sato, 2006 (JAST)81Fair | Death (CV and non-CV combined) (number of participants) | 2.1 | 426 | ASA | 10 (2.3%) | NR |
| 445 | No ASA | 9 (2.0%) |
| SPAF, 199176Good | Total mortality (number of participants) | 1.3 | 552 | ASA | 39 (7.1%) | ASA vs. Placebo: Risk Reduction 0.20 (95% CI, -0.20 to 0.46), p=0.37; RR 0.80 (95% CI, 0.54 to 1.2), p=NR |
| 568 | Placebo | 50 (8.8%) |
| Total mortality (rate per year) | 1.3 | 552 | ASA | 5.3 (NR) | NR |
| 568 | Placebo | 6.5 (NR) |

\*Adjusted by HF, angina, arrhythmias, digitalis, nitrates, beta-blockers, ventricular conduction defcts, ST depression, MI, cardiomegaly, smoking, sex, diuretics, gout meds, antiarrhythmic agents

†Adjusted by 54 baseline characteristics

‡Adjusted by age, vitamin E and beta-carotene treatment assignment

§Adjusted by age > 30 years, age > 50 years, male, nonwhite, type I and type II DM, clinical center

║Adjusted for baseline differences across the treatment groups

¶Adjusted for age and beta-carotene assignment

**Abbreviations**: ASA = acetylsalicylic acid; CI = confidence interval; HR = hazard ratio; NR = not reported; OR = odds ratio; RR = relative risk; vs = versus